skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

Original Research

(1944) Views  (630) Full article downloads

Authors: William Camu, Karim Hadjout, Sabine Latour, et al

Published Date May 2010 Volume 2010:4 Pages 127 - 133
DOI: http://dx.doi.org/10.2147/PPA.S10468

William Camu1, Karim Hadjout2, Sabine Latour3, Dieter Pöhlau4, Said Masri5

1MS Clinic, CHU Gui de Chauliac, University of Montpellier I, Montpellier, France; 2Department of Neurology, Centre Hospitalier, Rodez, France; 3Merck Serono S.A. – Geneva, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; 4Multiple Sclerosis Center, Kamillus-Klinik Asbach, Asbach, Germany; 5Praxis Masri, Berlin, Germany

Objective: To assess satisfaction with the serum-free formulation of subcutaneous (sc) interferon (IFN) beta-1a among patients with relapsing multiple sclerosis (MS).

Methods: Patients with relapsing MS who had been receiving sc IFN beta-1a for at least 6 months, were transitioned to the new formulation, 44 μg three times weekly. Patients were randomized to preventative ibuprofen (400 mg 30–60 minutes prior to injection) or ibuprofen as needed (PRN) for 4 weeks. The primary endpoint was the ‘flu-like’ symptom (FLS) domain score of the validated Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ).

Results: Of the 117 patients enrolled, 109 (93.2%) completed the study. Neither group’s MSTCQ FLS score showed a clinically meaningful change from baseline to week 4: mean ± SD changes were -1.1 ± 4.4 in the preventative ibuprofen group and 0.8 ± 3.6 in the ibuprofen PRN group. MSTCQ injection system satisfaction and global side-effect scores were unchanged; total and injection-site reaction scores improved moderately in both groups between baseline and week 4.

Conclusions: Results showed continued or increased levels of satisfaction with the new formulation of sc IFN beta-1a. FLS occurring with the new formulation were generally mild and seldom sufficiently bothersome to require ibuprofen treatment.

Keywords: multiple sclerosis, tolerability, ibuprofen, flu-like symptoms








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Clinical data management: Current status, challenges, and future directions from industry perspectives
Depression care and prevalence in HIV-positive individuals
Association between depression and development of coronary artery disease: pathophysiologic and diagnostic implications
Time-dependent effect in green synthesis of silver nanoparticles
Optimization of single-walled carbon nanotube solubility by noncovalent PEGylation using experimental design methods
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK